Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Ledermann, 2013, Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, 24, 10.1093/annonc/mdt333 Moschetta, 2020, Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?, Ann Transl Med, 8, 1710, 10.21037/atm-20-1683 Pujade-Lauraine, 2019, Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives, J Clin Oncol, 37, 2437, 10.1200/JCO.19.00194 Sandhu, 2013, The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial, Lancet Oncol, 14, 882, 10.1016/S1470-2045(13)70240-7 Moore, 2018, Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer, N Engl J Med, 379, 2495, 10.1056/NEJMoa1810858 González-Martín, 2019, Niraparib in patients with newly diagnosed advanced ovarian cancer, N Engl J Med, 381, 2391, 10.1056/NEJMoa1910962 Coleman, 2019, Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer, N Engl J Med, 381, 2403, 10.1056/NEJMoa1909707 Ray-Coquard, 2019, Olaparib plus bevacizumab as first-line maintenance in ovarian cancer, N Engl J Med, 381, 2416, 10.1056/NEJMoa1911361 Pujade-Lauraine, 2017, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 18, 1274, 10.1016/S1470-2045(17)30469-2 Penson, 2020, Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial, J Clin Oncol, 38, 1164, 10.1200/JCO.19.02745 Fong, 2010, Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval, J Clin Oncol, 28, 2512, 10.1200/JCO.2009.26.9589 Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728 Gelmon, 2011, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study, Lancet Oncol, 12, 852, 10.1016/S1470-2045(11)70214-5 Vanderstichele, 2019, Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer, J Clin Onc, 37, 5507, 10.1200/JCO.2019.37.15_suppl.5507 Boussios, 2019, Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review, Diagnostics (Basel), 9, 87, 10.3390/diagnostics9030087 Gordon, 2001, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J Clin Oncol, 19, 3312, 10.1200/JCO.2001.19.14.3312 Rose, 2005, Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer, Oncologist, 10, 205, 10.1634/theoncologist.10-3-205 Eetezadi, 2018, Ratio-dependent synergism of a doxorubicin and olaparib combination in 2D and spheroid models of ovarian cancer, Mol Pharm, 15, 472, 10.1021/acs.molpharmaceut.7b00843 Del Conte, 2014, Phase i study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours, Br J Cancer, 111, 651, 10.1038/bjc.2014.345 Boussios, 2020, Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach, Invest New Drugs, 38, 181, 10.1007/s10637-019-00867-4 Pujade-Lauraine, 2014, Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J Clin Oncol, 32, 1302, 10.1200/JCO.2013.51.4489 Colombo, 2019, BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC), Ann Oncol, 30, 851 Konstantinopoulos, 2019, Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma, JAMA Oncol, 5, 1141, 10.1001/jamaoncol.2019.1048 Zitvogel, 2010, Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway, Clin Cancer Res, 16, 3100, 10.1158/1078-0432.CCR-09-2891 Casares, 2005, Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J Exp Med, 202, 1691, 10.1084/jem.20050915 Ding, 2018, PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer, Cell Rep, 25, 2972, 10.1016/j.celrep.2018.11.054 Rivkin, 2015, A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients, J Clin Oncol, 33, 5573, 10.1200/jco.2015.33.15_suppl.5573 Oza, 2015, Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial, Lancet Oncol, 16, 87, 10.1016/S1470-2045(14)71135-0 Giaccone, 2010, A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors, J Clin Oncol, 28, 3027, 10.1200/jco.2010.28.15_suppl.3027 Khan, 2011, A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours, Br J Cancer, 104, 750, 10.1038/bjc.2011.8 Samol, 2012, Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase i study, Invest. New Drugs, 30, 1493, 10.1007/s10637-011-9682-9 Landrum, 2016, A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: an NRG Oncology/Gynecologic Oncology Group study, Gynecol Oncol, 140, 204, 10.1016/j.ygyno.2015.11.024 Mateo, 2016, An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib, Target Oncol, 11, 401, 10.1007/s11523-016-0435-8